Biosimilar pipelines for South Korean firms: Chong Kun Dang, DM Bio and HK inno.N

Biosimilars/General | Posted 31/05/2021 post-comment0 Post your comment

South Korea is becoming a more and more important spot on the map when it comes to biosimilars. Although Celltrion Healthcare (Celltrion) and Samsung Bioepis (Samsung and Biogen’s joint venture) are leading the way in Korea and worldwide, other Korean companies, such as Chong Kun Dang Pharmaceutical (Chong Kun Dang), DM Bio (joint venture between Dong-A ST and Meiji Holdings) and HK inno.N (previously CJ Healthcare), are also expanding their biosimilar pipelines.

22119008_l

Chong Kun Dang has three biosimilars in its pipeline at various stages of development, DM Bio also has three and HK inno.N has one, see Table 1.

Table 1: Biosimilar pipelines for South Korean firms: Chong Kun Dang, Dong‑A ST and HK inno.N
Company Product name Active substance Therapeutic area Stage of development
Chong Kun Dang CKD-11101 darbepoetin alfa Anaemia Approved in Japan [1]
CKD-12101 pegfilgrastim Neutropenia Preclinical
CKD-701 ranibizumab Degenerative myopia
Diabetes complications
Macular oedema
(Wet) AMD
Phase III
DM Bio DA‑3880 darbepoetin alfa Anaemia Approved in Japan [1]
DMB 3111 trastuzumab Early breast cancer
Metastatic breast cancer
Metastatic gastric cancer
Phase I trial completed in Japan. DM Bio licensed development and sales rights in Europe and Russia to Gedeon Richter, a Hungarian company [2]
DMB 3113 adalimumab Ankylosing spondylitis
Crohn’s disease
Juvenile rheumatoid arthritis
Psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Ulcerative colitis
Phase I trial started in Japan [3]
HK inno.N (formerly CJ Healthcare) CJ-40001 darbepoetin alfa Anaemia Phase III
AMD: age-related macular degeneration; PMDA: Pharmaceuticals and Medical Devices Agency.

 
Chong Kun Dang is leading the way in this group of companies, having obtained approval for its darbepoetin alfa biosimilar (CKD-11101) in Japan in December 2018 [4] and having a ranibizumab biosimilar in Phase III. While DM Bio, which is a joint venture between Dong-A ST and Meiji Holdings, is hot on its tail, having obtained Japanese approval in September 2019, licensing the drug to Sanwa Kagaku Kenkyusyo [4] and having trastuzumab and adalimumab biosimilars in Phase I.

Related articles
Approved biosimilars for South Korean firms: Celltrion and Samsung Bioepis

Biosimilar pipelines for South Korean firms: Celltrion and Samsung Bioepis

LATIN AMERICAN FORUM – Coming soon!

To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM – Próximamente!

Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

 
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of darbepoetin alfa [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 31]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-darbepoetin-alfa 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of trastuzumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 31]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-trastuzumab 
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of adalimumab [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 31]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-adalimumab 
4. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in Japan [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 May 31]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Off-patent biologicals/Biomimics approved in Bolivia
AGEMED V21I17MN
Biosimilars/General Posted 17/09/2021
Glosario de términos principales
20 AA010933
Biosimilars/General Posted 10/09/2021
Interactive map for interchangeable biosimilars
US map V18D13
Biosimilars/General Posted 10/09/2021
Biosimilars approved in Costa Rica
MinSalud Costa Rica V21I03
Biosimilars/General Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010